Traitements3programmes
Essais1liés
Publications0liées
SourceDBlocale

Traitements

3
MoléculeIndication / populationPhaseObjectifPaysRésultat
Spectris™ AD - ActiveThis is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device, Spectris™ AD, for 60 minutes daily for approximately 12 months. Efficacy will be measured using the Integrated Alzheimer's Disease Mini-Mental State Exam (MMSE) Activities of Daily Living (ADCS-ADL) Rating Scale (iADMARS). Alzheimer Non applicable À vérifier United States À vérifier
Spectris™ AD - ShamThis is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device, Spectris™ AD, for 60 minutes daily for approximately 12 months. Efficacy will be measured using the Integrated Alzheimer's Disease Mini-Mental State Exam (MMSE) Activities of Daily Living (ADCS-ADL) Rating Scale (iADMARS). Alzheimer Non applicable À vérifier United States À vérifier
Spectris™ AD - ActiveThis is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device, Spectris™ AD, for 60 minutes daily for approximately 12 months. Efficacy will be measured using the Integrated Alzheimer's Disease Mini-Mental State Exam (MMSE) Activities of Daily Living (ADCS-ADL) Rating Scale (iADMARS). Alzheimer Non applicable À vérifier United States À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
Spectris™ AD - Active Alzheimer Non applicable NCT05637801 A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) COMPLETED

Publications

0
MoléculeIndication / populationTitreJournalDate
Aucune publication.